Back to Search Start Over

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

Authors :
Centro para el Desarrollo Tecnológico Industrial (España)
Ministerio de Economía y Competitividad (España)
Ministerio de Sanidad y Consumo (España)
Fundación para la Investigación y la Prevención del Sida en España
Fundación Ramón Areces
Instituto de Salud Carlos III
Quer, Josep
Domingo, Esteban
Saudela, Silvia
Bes, Marta
Perales, Celia
Sheldon, Julie
Esteban, Juan Ignacio
Centro para el Desarrollo Tecnológico Industrial (España)
Ministerio de Economía y Competitividad (España)
Ministerio de Sanidad y Consumo (España)
Fundación para la Investigación y la Prevención del Sida en España
Fundación Ramón Areces
Instituto de Salud Carlos III
Quer, Josep
Domingo, Esteban
Saudela, Silvia
Bes, Marta
Perales, Celia
Sheldon, Julie
Esteban, Juan Ignacio
Publication Year :
2015

Abstract

All Rights Reserved. HepatitisCvirus(HCV)is classified into seven major genotypesand67 subtypes. Recent studies haveshownthat inHCVgenotype 1-infected patients, response rates to regimens containingdirect-acting antivirals(DAAs)are subtype dependent. Currently available genotypingmethods have limited subtyping accuracy.Wehave evaluated theperformanceof adeep-sequencing-basedHCVsubtyping assay, developed for the 454/GS-Junior platform, in comparisonwith thoseof two commercial assays (VersantHCVgenotype 2.0andAbbott Real-timeHCVGenotype II)andusingdirectNS5Bsequencing as a gold standard (direct sequencing), in 114 clinical specimenspreviously tested by first-generation hybridization assay (82 genotype 1and32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 callingbypopulation Sanger sequencing(69%1b,31%1a) in 81 specimensandidentified amixed-subtype infection (1b/3a/1a) in one sample. Similarly,amongthe 32previously indeterminate specimens, identical genotypeandsubtype results were obtained by directanddeep sequencing in all but four samples with dual infection. In contrast, both VersantHCVGenotype 2.0andAbbott Real-timeHCVGenotype II failed subtype 1 calling in 13 (16%) samples eachandwere unable to identify theHCVgenotype and/or subtype inmore than half of the nongenotype 1 samples.Weconcluded that deep sequencing ismore efficient forHCVsubtyping than currently available methodsandallows qualitative identificationofmixed infectionsandmay bemorehelpfulwith respect to informing treatment strategies withnewDAA-containing regimens across allHCVsubtypes.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1104778650
Document Type :
Electronic Resource